Ben Comer

Pittsburgh

Chief Editor at Life Science Leader

Chief Editor at Life Science Leader

Featured in: Favicon

lifescienceleader.com Favicon

informa.com Favicon

mmm-online.com Favicon

bioprocessonline.com Favicon

medtech.pharmaintelligence.informa.com

Articles

Companies To Watch: Vivani Medical

1 week ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Overcoming adherence and tolerability issues in obesity and diabetes treatment. Snapshot Vivani’s subdermal implant NanoPortal device, a platform drug delivery technology, is designed to deliver a near-constant and minimally fluctuating dose of an active pharmaceutical drug for a duration of six months, and potentially one year.
05.20.25 -- Business Of Biotech Newsletter

2 weeks ago | bioprocessonline.com | Ben Comer |Shetal Vyas |Denise N. Bronner |David W. Stowe

In the business of Uniquity Bio, Insmed, Chinese biotech and investment trends. Who — and what — is a life science leader in 2025? In the first month of my tenure as host of the Business of Biotech, it’s clearer to me than ever that leading in life sciences requires a constellation of expertise: strong leaders in drug development, in finance and operations, in policy and commercialization, and elsewhere. A broadening set of calculations is needed, to take and manage the risks required to succeed.
Promoting A Newly Approved Indication Against Established Competitors

3 weeks ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader There are lots of reasons why physicians and patients (and payers) might prefer one drug over another for the treatment of a given disease. Efficacy and safety are paramount, of course, but there are other factors, including drug price (and rebates), administration method, drug mechanism, an individual’s unique patient profile and history, as well as personal preferences for specific drug benefits or safety risks, compared with others.
Building Uniquity Bio: Teams, Capital, And Strategy

1 month ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader On a recent episode of the Business of Biotech podcast, Brian Lortie, president and CEO of Uniquity Bio, offered up useful advice about the complex process of building and leading a biotech startup in today's uncertain and evolving landscape.
Amgen's Ian Thompson On Leadership And A Global Mindset

2 months ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Riding for the British Cycling team was a foundational experience for Ian Thompson, SVP and general manager of U.S. business operations at Amgen. During a recent conversation about his 16-year tenure at Amgen, and what the future holds for one of biotech’s biggest success stories, Thompson consistently tied his approach to management and business strategy to lessons learned from cycling — uphill and down.
Companies To Watch: Imunon

2 months ago | lifescienceleader.com | Ben Comer

Article | March 31, 2025 Source: Life Science Leader By Ben Comer, Chief Editor, Life Science Leader Using targeted therapy to transform the standard of care in advanced ovarian cancer Snapshot With the recent sign-off from the FDA on protocols for a pivotal Phase 3 trial of IMNN-001 in advanced ovarian cancer, Imunon is poised to bring its IL-12 DNA plasmid vector (encased in a nanoparticle delivery system) into late-stage clinical trials.
A CEO With A General Counsel's Perspective

Feb 28, 2025 | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Should aspiring biopharmaceutical leaders focus on deep specialization and expertise in a singular area, or seek new and variable experiences across different parts of the business, developing a versatile skillset that can plug and play into leadership roles as needed?
FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance

Feb 21, 2025 | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Over the last 15 years, biopharmaceutical compliance departments, and chief compliance officers, have been better resourced, with more direct reporting lines to company leadership, than ever before. A big part of that is thanks to the many Corporate Integrity Agreements (CIAs) companies entered into with government agencies in the late 2000s and up through the present (for background, see my 2013 article in Pharmaceutical Executive).
Where Are They Now? Tarsus Pharmaceuticals

Feb 13, 2025 | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Then: In the May 2023 issue of Life Science Leader, Bobak Azamian, MD, Ph.D., cofounder and CEO of Tarsus Pharmaceuticals, talked about the company’s formation in 2016, and the decision to focus on the eyelid as a drug target, and on demodex blepharitis — an inflammatory condition caused by an overabundance of demodex mites — as a specific condition to treat.
Day One Bio Aims To Shorten the Time Gap On Cancer Treatments For Kids

Feb 7, 2025 | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader One of the biggest incentives for developing new therapies for rare pediatric cancers is the FDA’s rare pediatric disease Priority Review Voucher (PRV) program. If a drug in development meets the criteria for a PRV, the sponsor company, upon FDA approval, receives a PRV that can be redeemed for FDA priority review of a different pipeline product, or can be sold to another company.